PND15 Direct Medical Costs Related To Parkinson’s Disease  by Rodriguez Violante, M. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A59
the multiplier effect. This novel approach highlighted the unique characteristics 
of Alzheimer’s disease with particular focus on the additional costs and societal 
impact stemming from caring for a patient with Alzheimer’s. Future cost effective-
ness studies need to consider these additional impacts when quantifying their 
results and potential benefit to the health care system. Approaches to modelling 
long term disease impact must therefore be expanded to consider the wide reaching 
societal impact of Alzheimer’s disease to the direct health care costs.
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Objectives: To evaluate patterns of adjunctive therapy with anti-epileptic drugs 
(AED) and AED-specific pharmacy costs among patients with epilepsy over a six-
year time period (2006-2011). MethOds: Study patients were identified from the 
2006-2011 PharMetrics Plus Database. Separate patient cohorts were created for each 
year of analysis. Patients ≥ 18 years of age with ≥ 2 claims for epilepsy (ICD-9-CM 
345.XX) who were continuously eligible for the entire calendar year were selected. 
Demographic characteristics, proportion of patients with adjunctive AED therapy 
(defined as a ≥ 60 day overlap in supply for two different AEDs) and AED phar-
macy costs were evaluated for each calendar year. Overall adjunctive AED therapy 
utilization was further stratified by AED generic/brand status using the following 
categories: adjunctive therapy with two generic AEDs, two branded AEDs, or one 
generic and one branded AED. AEDs were identified and categorized based on NDC 
codes indicative of a generic/branded therapy for each year. Results: Patients 
meeting cohort selection criteria varied for each year of analysis, ranging from 
28,013 to 61,444 (mean age 44.6-46.3 years). The proportion of patients on adjunc-
tive AED therapy stayed relatively constant over the analysis period, increasing only 
slightly over time (2006: 21.2%, 2007: 24.1%, 2008: 23.9%, 2009: 23.9%, 2010: 24.6%, 
2011: 24.7%). Adjunctive generic AED therapy utilization approximately doubled 
over the analysis period (2006: 11.5%, 2011: 21.7%), while branded therapy decreased 
5-fold (2006: 3.1%, 2011: 0.6%) and generic/branded decreased by > 50% (2006: 11.1%, 
2011: 4.9%) adjunctive AED therapy decreased (all P< 0.01). Over the six-year analysis 
period, mean AED pharmacy costs among patients with epilepsy on any adjunctive 
AED therapy decreased by 7.6% (2006: $4,090, 2011: $3,778; P< 0.01). cOnclusiOns: 
In this study, a doubling in the utilization of generic drugs over a six-year period 
was associated with a 7.6% decrease in pharmacy cost.
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Objectives: Because of the risk of progressive multifocal leukoencephalopathy 
(PML), natalizumab is generally recommended as second-line treatment for relaps-
ing-remitting multiple sclerosis (RRMS) patients. For those negative for anti-JC virus 
antibodies, the natalizumab associated risk of PML is low. The objective was to 
estimate the cost-effectiveness of first-line natalizumab versus second-line natali-
zumab treatment (i.e., initiate glatiramer acetate (GA) then switch to natalizumab) 
for RRMS patients negative for anti-JC virus antibodies. MethOds: We used a cohort 
simulation model to estimate the 20-year costs and outcomes of first- and second-
line natalizumab treatment. Model inputs included published natural history pro-
gressions of the Expanded Disability Status Scale (EDSS), treatment effects from 
randomized controlled trials on disease progression and relapse rates, risk of PML, 
and utilities. We used the PharMetrics Plus claims database for total costs, switching 
and discontinuation rates and their associated costs (i.e., first-line treatment with 
GA then switch or discontinue). Outputs for the average patient, discounted at 3% 
per annum, were quality-adjusted life years (QALYs), costs in 2012 US dollars, and 
incremental cost-effectiveness ratios (ICERs). Results: Compared to natalizumab 
as second-line treatment after switching from GA, first-line natalizumab treatment 
was associated with 0.40 incremental QALYs gained, $36,779 more in 20-year costs 
for an ICER of $91,510 per QALY. Compared to first-line GA treatment without switch-
ing, first-line treatment with natalizumab was associated with an ICER of $95,764 
per QALY (likelihood = 0.56 that first-line natalizumab treatment was cost-effective 
at a willingness-to-pay of $100,000 per QALY). First-line natalizumab treatment 
dominated second-line natalizumab treatment when compared to GA treatment 
without switching through principles of extended dominance. cOnclusiOns: 
Treating JC virus negative RRMS patients with natalizumab as a first-line treatment 
provided better value compared to natalizumab use as a second-line agent. More 
aggressive treatment with natalizumab should be considered for RRMS patients 
who are negative for anti-JC virus antibodies.
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Objectives: To compare the cost-effectiveness of fingolimod, teriflunomide, dime-
thyl fumarate and IM IFN β -1a as first-line therapies in treatment of patients with 
Relapsing-Remitting Multiple Sclerosis (RRMS). MethOds: A Markov model was 
developed to simulate the disease progression and to evaluate the cost-effectiveness 
of disease-modifying drugs from a US societal perspective. The time horizon in base 
AD shows a potential budget impact of approximately Brz3,9 million (US$1,8 million) 
for 5 consecutive years. cOnclusiOns: The use of Souvenaid®, a new approach 
in the management of mild AD, can benefit approximately 100.000 patients with 
AD in 5 years and it is estimated to have a relatively small budget impact to SUS, 
since the projections of cost of disease for the same period are Brz154 million and 
potential budget impact of approximately Brz3,9 million.
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Objectives: Parkinson´s disease is a neurodegenerative disorder with an estimated 
incidence of 40-50 cases per 100,00 habitants per year. In this paper, We set out to 
estimate the direct medical costs of Parkinson´s disease. In addition, direct medical 
costs according to age, gender, socio-economic level, severity and educational attain-
ment were evaluated. MethOds: A partial economic evaluation was performed in 
order to analyse the direct medical costs related to Parkinson´s disease. The analysis 
took the perspective of the National Institute of Neurology and Neurosurgery (INNN) 
for the first semester of 2013, including outpatient clinic visits, medications, medi-
cal procedures and laboratory tests, these costs were provided from the INNN´s 
financial managment. A mexican retrospective study of patients having Parkinson´s 
disease from the INNN provided information on severity, baseline characteristics 
and socio-demographic characteristics. Results: Mean first semester direct medi-
cal costs per patient on Parkinson´s disease were US$2 366 in 2013. When analyz-
ing cost distribution, no differences were found in the direct medical costs for 
the modality groups. In severity and gender, costs hadn´t statistical significance 
(p-value> .05). On the other hand, costs by grouped age, grouped socio-economic 
level and educational attainment were statistically different (p-value< .001). Finally, 
in the generalized linear model analysis, direct medical costs were only predicted by 
grouped socio-economic level; age, gender, severity or years of schooling weren´t sta-
tistically sgnificance in the model. cOnclusiOns: The first semester direct medical 
costs per patient on Parkinson´s disease in this study were US$2 366 in 2013. Total 
direct medical costs by grouped age and educational attainment were statistically 
different for patients having Parkinson´s disease. In a multivariate analysis, only 
socio-economic level predicted a higher direct medical cost.
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Objectives: To review studies that investigated the direct and indirect costs of care 
for Parkinson’s disease (PD) in China. MethOds: A structured literature review 
on published articles in both English and Mandarin languages was conducted. 
Literature search was conducted using PubMed, Cochrane, WAN FANG, and VIP 
databases. Articles published between 2000 and 2013 were selected. The inclusion 
criteria included studies on Chinese population based in China only and studies that 
reported direct or indirect cost of PD treatment, management as well as economic 
burden of PD. Four reviewers (two for each language) independently selected and 
reviewed the articles. Subjective quality assessment of the selected articles were 
performed. Direct cost included cost of outpatient consultation, hospitalisation, 
medication, rehabilitation and the use of prescribed traditional Chinese medicine; 
whereas indirect cost included home care, transport, home support equipment, 
supplement use, and productivity loss. Results: Eleven articles (10 Mandarin and 1 
English) were selected and reviewed qualitatively. Approximately 80% of the articles 
reviewed received an average grade in terms of study quality. The average direct 
and indirect cost of managing PD in China reported ranged from RMB 7,000 (USD 
1,157) to RMB 15,000 (USD 2,479) per annum. The reported direct cost of managing 
PD ranged from RMB 1,600 (USD 265) to RMB 13,000 (USD 2,149); whereas the indirect 
cost reported ranged from RMB 2,970 (USD 491) to RMB 13,200 (USD 2,182). Seven 
out of 11 articles reported cost-effectiveness results. Three papers from the same 
authors had reported the main factors affecting the overall economic burden of 
PD. cOnclusiOns: Various combination therapy involving levodopa had higher 
direct costs but reduced indirect costs compared to levodopa monotherapy. In gen-
eral, the reported indirect cost is higher than direct cost of PD management in China.
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Objectives: To estimate the indirect burden of Alzheimer’s disease in 
US. MethOds: Applying the economic concept of the multiplier effect – the degree 
to which a change in aggregate demand may have a greater effect on national 
income – to the analysis of the indirect cost of Alzheimer’s disease can provide 
valuable insights to the societal burden of the disease. US demography forecasts and 
disease incidence rates were used to develop a Markov model for the Alzheimer’s 
patient population. Estimates for the indirect cost of Alzheimer’s were derived 
using key variables, such as hours spent on care per patient, severity of the illness, 
percentage in need of care by disease severity, and salaries. Results: The model 
predicted that the indirect burden of Alzheimer’s will increase by 85% from 2015-
2020, by 33% from 2020 to 2025 and by 17% from 2025-2030. The main cost drivers in 
the model are the unpaid work by carers and lost revenues due to mild Alzheimer’s 
patients having to leave the labor market. cOnclusiOns: By employing the mul-
tiplier model it was determined that the indirect costs attributed to Alzheimer’s 
disease have a significant impact on the total burden of the disease, due in part to 
